At present, the therapeutic approach primarily involves the use of SGLT2 inhibitors, coupled with rigorous management of the risk factors, such as hypertension, diabetes, hyperlipidemia, and weight control [26]. Here, SLC5A2 is linked to hyperlipidemia.